Agios Pharmaceuticals reported $-121.58M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Astellas Pharma JPY 134.54B 30.13B Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025